Sustained release d-amphetamine reduces cocaine but not 'speedball'-seeking in buprenorphine-maintained volunteers: a test of dual-agonist pharmacotherapy for cocaine/heroin polydrug abusers.
Sustained release d-amphetamine reduces cocaine but not 'speedball'-seeking in buprenorphine-maintained volunteers: a test of dual-agonist pharmacotherapy for cocaine/heroin polydrug abusers.
复制标题
DOI:
10.1038/npp.2010.175
复制
发表时间:
2010-12
期刊:
影响因子:
--
通讯作者:
中科院分区:
文献类型:
--
作者:
The aim of this study was to determine whether oral sustained release d-amphetamine (SR-AMP) reduces cocaine and opioid/cocaine combination (‘speedball’-like) seeking in volunteers with current opioid dependence and cocaine dependence. Following outpatient buprenorphine (BUP) 8mg/day stabilization without SR-AMP, 8 participants completed a 3-week inpatient study with continued BUP 8 mg/day maintenance and double-blind ascending SR-AMP weekly doses of 0, 30 and 60 mg/day, respectively. After 3 days (Sat–Mon) stabilization at each SR-AMP weekly dose (0, 15 or 30 mg administered at 0700 and 1225 each day), on Tue–Fri mornings (0900–1200) participants sampled 4 drug combinations in randomized, counterbalanced order under double-blind, double-dummy (intranasal cocaine and intramuscular hydromorphone) conditions: Cocaine (COC 100 mg + saline); Hydromorphone (COC 4 mg + HYD 24 mg); “Speedball” (COC 100 mg + HYD 24 mg); and Placebo (COC 4 mg + saline). Subjective and physiological effects of these drug combinations were measured. From 1230–1530, participants could respond on a choice, 12-trial progressive ratio schedule to earn drug units (1/12th of total morning dose) or money units ($2). SR-AMP significantly reduced COC, but not HYD or speedball, choices and breakpoints. SR-AMP also significantly reduced COC subjective (e.g. abuse-related) effects and did not potentiate COC-induced cardiovascular responses. This study demonstrates the ability of SR-AMP to attenuate COC self-administration, as well as its selectivity, in cocaine/heroin polydrug abusers. Further research is warranted to ascertain whether SR-AMP combined with BUP could be a useful dual-agonist pharmacotherapy.
登录
查看更多内容
影响因子:
3.4
作者:
Comer, SD;Walker, EA;Collins, ED
通讯作者:
Collins, ED
影响因子:
4.2
作者:
Comer, S. D.;Ashworth, J. B.;Walsh, S. L.
通讯作者:
Walsh, S. L.
影响因子:
2.3
作者:
Downey, KK;Helmus, TC;Schuster, CR
通讯作者:
Schuster, CR
影响因子:
4.2
作者:
Greenwald, Mark K.
通讯作者:
Greenwald, Mark K.
影响因子:
3.6
作者:
Foltin, RW;Evans, SM
通讯作者:
Evans, SM